

1 **Title:** Changes in life expectancy and life span equality during the COVID-19 epidemic

2 in Japan up to 2022.

3 **Article type:** Original Article

4

5 Authors:

6 Yuta Okada^a, Hiroshi Nishiura^a

7 ^a Graduate School of Medicine, Kyoto University, Kyoto 6068503, Japan

8

9 Correspondence to: Hiroshi Nishiura

10 Address: Kyoto University, Yoshidakonoecho, Sakyo, Kyoto city, Kyoto 6068503,

11 Japan

12 Tel: +81-75-753-4456; Fax: +81-75-753-4458

13 Email: nishiura.hiroshi.5r@kyoto-u.ac.jp

14

15

16 **Abstract**

17 Demographic analyses enable the evaluation of the impact of COVID-19 on life
18 expectancy. We evaluated the relationship between the life expectancy change from
19 2020–21 and 2021–22 and COVID-19 epidemic size at prefectural level in Japan. We
20 also conducted age- and cause-specific decomposition of life expectancy change.
21 Trends in life span equality from 2000–22 were evaluated at the national level.
22 Prefectural analysis of 2021–22 life expectancy change and annual per-population
23 COVID-19 cases, person-days in intensive care, and reported COVID-19 deaths showed
24 no significant correlations, unlike our analysis from 2020–21. However, decomposition
25 analysis revealed substantial life expectancy shortening attributable to the population
26 over 35 years old. It also showed large increases in causes of death such as
27 cardiovascular or respiratory disorders as well as COVID-19. Whole-population life
28 span equality declined in 2020 but increased in 2021 and 2022 despite the shorter life
29 expectancy. The discrepancy between life expectancy change and COVID-19 statistics
30 in 2022 suggests the growing ascertainment bias of COVID-19. The increased
31 contribution of cardiovascular disorders to life expectancy shortening is an alarming
32 sign for the future. Life span equality changes in 2021 and 2022 can probably be
33 attributed to increased mortality among older people.

34

35 **Keywords:** COVID-19; life expectancy; excess mortality; Arriaga Method; life span

36 equality; Japan

37 **Introduction**

38 Since the start of the COVID-19 pandemic in Wuhan, China in November 2019,
39 evidence of the pandemic's impact on mortality has accumulated globally, with
40 substantial geographical heterogeneity.¹⁻⁶ Global studies suggest that from January 1st,
41 2020 to December 31st, 2021, excess deaths worldwide were in the range of 14.9–15.9
42 million, with a large proportion attributed to India and the United States.^{3,4} Published
43 studies suggest that the global life expectancy change was –1.6 years from 2019 to
44 2021, when many countries showed bounce-backs from the shortening in 2020.
45 However, other countries faced sustained shortening into 2021.⁴⁻⁶

46 It is now several years since the emergence of COVID-19, and the evaluation of the
47 mortality impact of the condition has become more difficult for several reasons. One
48 reason is changes in the official COVID-19 statistics, which are provided by public
49 health agencies around the world and reflect epidemic activity. These are now less
50 rigorous than in 2020, because most countries have gradually diminished their effort

51 either to control the spread of COVID-19 or to maintain a meticulous surveillance
52 system. Another reason is the change in the nature of deaths associated with COVID-19
53 since the introduction of vaccines against the disease in late 2020. The direct mortality
54 impact of COVID-19 has been alleviated by these vaccines, but a substantial proportion
55 of deaths are caused indirectly through complications such as cardiovascular disorders,
56 or by limited access to healthcare services when the healthcare capacity or ambulance
57 system were overwhelmed by the increased case load pressure of COVID-19.^{5,7-15} The
58 ongoing emergence of SARS-CoV-2 variants with a high capability of immune evasion
59 and transmission may have worsened the health impact of COVID-19, but
60 understanding the true burden has remained a challenging task.^{16,17}

61 Direct approaches to estimating the mortality impact of COVID-19 are therefore
62 challenging, including in Japan. There, the epidemic size of COVID-19 was greatest
63 upon the emergence of SARS-CoV-2 Omicron (B.1.1.529) lineage variants. In line with
64 other regions, Japan has been severely affected by COVID-19 in terms of excess
65 mortality and life expectancy shortening.^{1,3-5,14,18-21} The updated estimates by the
66 National Institute of Population and Social Security Research suggest that life
67 expectancy at birth has shortened for two consecutive years, from 84.58 years in 2021
68 to 84.10 in 2022 for the total population. However, it is not clear whether the cause-

69 specific impact of this shortening has changed since 2021. It is also not clear how the
70 contribution of cardiovascular, respiratory, and neoplastic disorders in 2021 have
71 changed.¹⁸ From a demographic perspective, the change in life span equality during and
72 since the COVID-19 pandemic is also interesting. One measure of life span equality, or,
73 evenness of life span, is the logarithm of the inverse of life table entropy. Global and
74 historical demographic analysis suggests that the trends in life expectancy at birth and
75 life span equality have been in line with each other.^{22,23} However, this might not be the
76 case when the age–mortality structure changes drastically. For example, during the
77 COVID-19 epidemic in Japan, the mortality increase in 2021 contributed substantially
78 to shorter life expectancy.¹⁸

79 To examine the demographic impact of the COVID-19 epidemic in 2022 in Japan, we
80 investigated the relationship between reported COVID-19 burden at the prefectural level
81 and life expectancy. We also decomposed the year-on-year life expectancy change from
82 2019–22 by age groups and major causes of death, and evaluated the lifetime loss by
83 age and life span equality during the COVID-19 epidemic.

84

85 **Results**

86 The life expectancy at birth in Japan for the total, male, and female populations
87 from 2019–2022 is shown in Supplementary Table 1. These results were based on
88 abridged life tables that we re-calculated for use in Arriaga decomposition, but which
89 are almost identical to results provided by JMD. The life expectancy of the total
90 population decreased by 0.49 years, from 84.59 to 84.10 from 2021–22. A decrease in
91 life expectancy was also seen from 2020–21 of 0.15 years (from 84.74 to 84.59 years).
92 However, the magnitude of the shortening was greater in 2021–22. The shortening of
93 life expectancy at birth for both male and female populations also increased from 2021–
94 22, by 0.43 years for men (from 81.49 to 81.06 years) and 0.50 years for women (from
95 87.62 to 87.12 years).

96 Figure 1 shows life expectancy changes in the total population by prefecture in
97 2019–20, 2020–21, and 2021–22. Following the drastic change from an overall
98 increasing trend in 2019–20 to a sharply decreasing trend in 2020–21, all but one
99 prefecture saw a decline in life expectancy from 2021–22. In 2022, the greatest decrease
100 in life expectancy was seen in Iwate (1.00 years), and the only prefecture where life
101 expectancy continued to increase was Nagasaki (0.05 years). The prefecture-level life

102 expectancy changes of the male and female populations were largely consistent with
103 that for the total population (for the details, see Supplementary Data).

104 Figure 2 shows the correlation between reported COVID-19 burden and life
105 expectancy changes at the prefectural level. Combined with the linear regression results
106 shown in Table 1, there was no obvious correlation between annual reported cases,
107 person-days in intensive care, and death due to COVID-19 in 2021–22. However, this
108 was contrary to the findings from 2020–21.

109 Figure 3 shows the results of the Arriaga decomposition of life expectancy
110 change by age groups and major causes of death. An aggregated summary by age
111 groups and causes of death is shown in Supplementary Figures 1 and 2. There was a
112 clear negative contribution among the older population in 2020–21, and this negative
113 contribution was even bigger in 2021–22. The age range of the group contributing to the
114 reduction also widened in 2021–22 to as low as 30–34 years.

115 Figure 3 also shows the contributions of major causes of death by age groups.
116 The negative contribution of COVID-19 among the older population expanded
117 substantially in 2021–22. The total contribution by all ages grew from -0.095 years in
118 2020–21 to -0.131 years in 2021–22. In addition to COVID-19, the negative
119 contribution of cardiovascular causes also grew considerably in 2021–22, especially

120 among those over 50 years old. The total contribution of cardiovascular death was
121 -0.091 years in 2022, which was a consistent and substantial reduction compared with
122 $+0.073$ years in 2020 and -0.003 years in 2021. The negative contribution of “other”
123 causes (the remaining causes of death beyond the top nine major categories) also
124 increased substantially in 2021–22 among the population over 50 years old, with a total
125 of -0.139 years across all age groups. There was a clear decrease in the contribution of
126 respiratory and neoplastic disorders, and other causes from 2020–21 to 2021–22 (see
127 Supplementary Data for detailed results). Results from the decomposition analysis for
128 the male and female populations were similar to that of the total population
129 (Supplementary Data and Supplementary Figures 3 and 4).

130 The values of $h(t)$ as an indicator of life span equality for the total population
131 from 2000 to 2022 are shown in Figure 4. Panel (A) shows that h largely increased
132 consistently up to 2019, except in 2011 when an exceptional number of casualties
133 occurred due to the earthquake and tsunami that hit eastern Japan. That increasing trend
134 was halted in 2020 when the COVID-19 pandemic started, but has resumed since 2021.
135 The values of $h(t)$ for the female and male populations showed very similar patterns to
136 those for the total population (Supplementary Figures 5 and 6). Panel (B) in Figure 4
137 shows the relationship between $h(t)$ and life expectancy at birth from 2000 to 2022. A

138 decrease in $h(t)$ was seen in 2020 for the first time since 2011, and was followed by an
139 increase in 2021 and 2022 despite the shortening of life expectancy at birth.

140 To see how the overall dynamics of $h(t)$ from 2020 to 2022 can be explained
141 by mortality improvements by age for this period (in relation to a^H), we calculated
142 curves of $w(x, t)W_h(x, t)$ across ages for 2021 and 2022. (Figure 5A) We also
143 evaluated the year-on-year mortality improvement $r(x, t)$ from 2020 to 2022 for the
144 total population (Figure B). As in panel A of Figure 5, the curves of $w(x, t)W_h(x, t)$ for
145 2021 and 2022 for the total population were very similar, although there was a slight
146 shift toward the younger ages in the negative part of the curve for the older population.
147 As for $r(x, t)$, $r(x, 2020)$ above $x = a^H$ lay in the positive range, whereas $r(x, 2021)$
148 and $r(x, 2022)$ mostly lay in the negative range for the age range as seen in panel B of
149 Figure 5. For ages younger than $x = a^H$, the signs of $r(x, 2020)$, $r(x, 2021)$, and
150 $r(x, 2022)$ were inconsistent across different ages, suggesting that increased mortality
151 among those older than a^H clearly contributed to the increase of $h(t)$ in 2021 and 2022
152 (see Supplementary Figures 6 and 7 for results on the female and male populations).

153 **Discussion**

154 Our study showed the pattern of deaths in Japan during the COVID-19
155 epidemic (up to 2022) through demographic information. The main finding was the
156 growing impact of the older population and cardiovascular deaths on the shortening of
157 life expectancy, which was considerable from 2021 to 2022. The lack of significant
158 correlations between life expectancy change and epidemiological indicators of the
159 COVID-19 burden from 2022 is also a concern. This finding may be linked to the low
160 detection of COVID-19 cases and associated deaths, which is supported by our results
161 about the age- and cause-specific contributions to life expectancy change. The
162 increasing trend in life span equality despite the life expectancy shortening may also be
163 related to the substantial increase in mortality among the older population.

164 There were two key findings from our study. The first was that all age groups
165 over 30 years old contributed to the shortening of life expectancy in 2022, as shown in
166 Figure 3 and Supplementary Figure 1. However, compared with the overall shortening
167 attributed to age groups over 50 in 2021, the negative impact was more diffuse across
168 ages. This finding is similar to what was observed in 2020–21 in countries in Eastern
169 Europe, though the underlying situations in these countries, such as types of circulating
170 SARS-CoV-2 variants, vaccine coverage, and healthcare situations, would have been

171 quite different from that in Japan from 2021–22.⁵ In Japan, the population-wide vaccine
172 coverage of the second dose of mRNA vaccines (BNT162b2 [Pfizer/BioNTech] and
173 mRNA-1273 [Moderna] vaccines) was around 80% by the end of 2021, and the
174 coverage of the third dose also increased from around 15% at the end of 2021 to 68% by
175 the end of 2022.²⁴ Despite this high vaccination rate, we found substantial mortality
176 caused by COVID-19 in Japan among wider age groups in 2022. This was not fully
177 captured by COVID-19 statistics, as seen in our prefectural analyses (Figure 2 and
178 Table 1).

179 Another key finding was the substantial growth in the negative contribution of
180 cardiovascular disorders to life expectancy shortening, especially among populations
181 over 50 years old (Figure 3 and Supplementary Figure 2). This was not surprising,
182 because published studies have shown an elevated risk of cardiovascular diseases
183 associated with COVID-19.^{12–14,25} However, to our knowledge, our study is the first to
184 have quantified the magnitude of life expectancy shortening in Japan caused by
185 cardiovascular deaths in 2022. The negative change in contributions by respiratory
186 causes from 2021 to 2022 and the consistently negative trend in contributions by
187 neoplastic disorders since 2020 are also of note. In addition to COVID-19-associated
188 conditions, these findings may be attributable to an array of factors including changes in

189 hospital attendance.¹⁸ There is a gap between these findings and the global and regional
190 cause-specific contributions to life expectancy change from 2019–21.²⁶ Further update
191 on this issue is warranted to evaluate changes in life expectancy change by causes of
192 death. The increase in the contribution of remaining causes of death is mostly explained
193 by the increase in deaths due to senility, which increased by around 20,000 in 2021 and
194 27,000 in 2022.²⁷

195 The changes in life span equality during the COVID-19 pandemic were also of
196 note. Our result highlights the undesirable increase in life span equality despite the
197 shortening of life expectancy at birth. This was in line with the substantial negative
198 contribution by the older population to life expectancy changes in the same period,
199 highlighted by the Arriaga decomposition results. These findings add to demographic
200 case studies on the historical relationship between life expectancy and life span
201 equality.^{22,23}

202 Our study had some limitations. First, we could not examine the relationship
203 between COVID-19 and other causes of death in detail at the prefectural level, because
204 data on prefectural death count stratified by age and cause of death are not openly
205 accessible. Detailed analysis of prefectural data would have provided insights on
206 geographic heterogeneity, and we hope to explore this in future. Second, we ignored

207 geographic and temporal variation in the ascertainment bias for COVID-19 statistics.
208 We sufficiently met our key focus to be confident about the true mortality burden of
209 COVID-19, but these factors could have biased our analysis of the relationship between
210 prefectural COVID-19 statistics and life expectancy change. Third, we did not consider
211 the fluctuation in the coverage of death registrations in Japan from 2019–22. However,
212 it is unlikely that we missed a large proportion of deaths that would substantially affect
213 our results, because the completeness of death registration is reported to be 90–99% in
214 Japan.²⁸

215 In conclusion, our demographic analysis showed the impact of the COVID-19
216 epidemic up to 2022, when the epidemic grew substantially larger. The demographic
217 burden of the pandemic increased more in 2022 than in 2021 or before, but the COVID-
218 19 burden reported by epidemiological surveillance failed to capture this trend. This is
219 probably due to both the shrinking coverage of epidemiological surveillance and the
220 growing impact of COVID-19-associated deaths caused by complications such as
221 cardiovascular disorders. We also showed an undesirable increase in life span equality
222 due to disproportionately higher mortality among older people. Our study therefore
223 provides valuable insights into the mortality impact of the COVID-19 epidemic in

224 Japan, which can now only be captured by indirect measures such as demographic

225 analysis in the absence of meticulous epidemiological surveillance.

226 **Methods**

227 **Epidemiological data**

228 We used the data on deaths and exposure-to-risk populations available in the
229 Japanese Mortality Database (JMD), which was available for the whole of Japan and by
230 prefecture.²⁹ Death counts by cause of death and age group were obtained from the vital
231 statistics published by the Ministry of Health, Labour and Welfare of Japan.³⁰ In line
232 with a previous study, we categorized major causes of death using the International
233 Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-
234 10) into the top nine major cause categories (based on death counts by cause in 2022),
235 and aggregated the remainder into a single group, to give a total of ten groups.¹⁸ The
236 epidemiological data for COVID-19 were retrieved from the open-access data provided
237 by the Ministry of Health, Labour and Welfare.³¹

238 **Calculation of period life table**

239 For subsequent use for age- and cause-specific decomposition of life expectancy
240 gaps, we re-calculated period life tables from 2000 to 2022 for the whole of Japan and

241 for all prefectures as described before.^{18,27} We obtained age group-specific mortality
242 m_x using death counts and exposure-to-risk population in each age group x . Using m_x
243 and a_x , the average length of time to death in deceased individuals in age group x , we
244 calculated q_x , the probability of death in age group x as:

$$245 \quad q_x = \begin{cases} \frac{m_x w_x}{1 + (w_x - a_x) m_x}, & x = 0, 1-4, 5-9, \dots 95-99, \\ 1, & x = 100+, \end{cases}$$

246 where w_x is the time interval of age group x . Starting from an initial population

$$247 \quad l_0 = 100,000,$$

248 l_x can be obtained by iteratively applying the formula:

$$249 \quad l_{x+1} = l_x(1 - q_x),$$

250 for age groups $x = 0, 1-4, 5-9, \dots 100+$ (in years). Using l_x and a_x values,

$$251 \quad L_x = w_x l_{x+1} + a_x d_x = w_x l_{x+1} + a_x l_x q_x,$$

$$252 \quad T_x = \sum_{i=x}^{100+} L_i,$$

253 where L_x is the person-years spent in age group x , $d_x = l_x q_x$ is the number of deaths in

254 age group x , and T_x is the person-years of life remaining for those in age group x . The

255 life expectancy of age group x , e_x , is then calculated as:

$$256 \quad e_x = \frac{T_x}{l_x},$$

257 and the life expectancy at birth is calculated as $e_0 = T_0/l_0$.

258 **Life expectancy change and COVID-19 statistics at the prefectural level**

259 Three COVID-19 statistics at prefectural level were used for this analysis: (i)
260 annual number of COVID-19 cases, (ii) annual number of person-days in intensive care
261 because of COVID-19, and (iii) annual number of documented deaths due to COVID-
262 19. Using each of the COVID-19 indicators as an explanatory variable, we used linear
263 regression analysis to predict the year-on-year life expectancy change as the dependent
264 variable for 2020–21 and 2021–22.

265 **Decomposition of annual life expectancy change by age and cause of death**

266 In line with a recent study, we used the Arriaga method for age- and cause-
267 specific decomposition of life expectancy change.^{18,32,33} The total contribution of age
268 group x to the life expectancy change (in years) from year y to year $y + 1$, denoted as
269 C_x , can be described as:

$$270 \quad C_x = \left[\frac{l_x^y}{l_0} \left(\frac{L_x^{y+1}}{l_x^{y+1}} - \frac{L_x^y}{l_x^y} \right) \right] + \left[\frac{T_{x+1}^{y+1}}{l_0} \left(\frac{l_x^y}{l_x^{y+1}} - \frac{l_{x+1}^y}{l_{x+1}^{y+1}} \right) \right]. \quad (1)$$

271 We then decomposed C_x into cause-specific contributions:

$$272 \quad C_x^i = C_x \left[\frac{R_x^{i,y+1} m_x^{y+1} - R_x^{i,y} m_x^y}{m_x^{y+1} - m_x^y} \right], \quad (2)$$

273 where C_x^i is the contribution of cause of death i in age group x , R_x^i is the proportion of
274 deaths in age group x associated with cause i , and m_x is the overall mortality rate in age
275 group x .

276 **Life span equality h**

277 We used a measure of life span equality h , which was derived from life table
278 entropy \bar{H} .^{22,34-36} Life table entropy $\bar{H}(t)$ is a measure of variation, or inequality, in life
279 span at time t that is defined as:

$$280 \quad \bar{H}(t) = -\frac{\int_0^{\infty} l(x, t) \ln(l(x, t)) dx}{\int_0^{\infty} l(x, t) dx} = \frac{e^{\dagger}(0, t)}{e_0(t)},$$

281 where $e^{\dagger}(0, t)$ is the special case of:

$$282 \quad e^{\dagger}(x, t) = -\frac{\int_x^{\infty} l(a, t) \ln(l(a, t)) da}{l(x, t)} = \frac{\int_x^{\infty} d(x, t)e(x, t)dx}{l(x, t)},$$

283 which is the life disparity, or the life expectancy loss after birth, and e_0 is the life
284 expectancy at birth. Using $\bar{H}(t)$, life span equality $h(t)$ is defined as:

$$285 \quad h(t) = -\log(\bar{H}(t)).$$

286 Note that, contrary to $\bar{H}(t)$, the value of $h(t)$ is the measure of life span equality. We
287 used a 1×1 year life table provided by JMD to calculate $h(t)$ from 2000 to 2022 for

288 total, male, and female populations, and evaluated the relationship between $h(t)$ and
289 life expectancy at birth, $e_0(t)$, for each of these populations.²⁹

290 Aburto et al.²² described the variation of $h(t)$ over time as:

$$291 \quad \frac{\partial h}{\partial t} = -\frac{\frac{\partial \bar{H}}{\partial t}}{\bar{H}} = \int_0^{\infty} w(x, t) W_h(x, t) \rho(x, t) dx,$$

292 where

$$293 \quad \rho(x, t) = -\frac{\frac{\partial \mu(x, t)}{\partial t}}{\mu(x, t)} = -\frac{\partial}{\partial t} \log(\mu(x, t))$$

294 is the mortality improvement in age x over time,

$$295 \quad w(x, t) = \mu(x, t) l(x, t) e(x, t) = d(x, t) e(x, t)$$

296 is the weight of the contribution of $\rho(x, t)$ to life expectancy change in age x , and

$$297 \quad W_h(x, t) = \frac{1}{e_0} - \frac{1}{e^+(0, t)} (H(x, t) + \bar{H}(x, t) - 1)$$
$$298 \quad = \frac{1}{e_0} - \frac{1}{e^+(0, t)} \left(\int_0^x \mu(x, t) dx + \frac{e^+(x, t)}{e(x, t)} - 1 \right).$$

299 Thus, $w(x, t) W_h(x, t)$ can be considered as the weight, or sensitivity, of $h(t)$ to $\rho(x, t)$

300 at age x . We calculated $w(x, t) W_h(x, t)$ and the threshold age a^H that satisfies

301 $W_h(a^H, t) = 0$ for $t = 2000, 2001, \dots, 2022$. These results were compared with year-

302 on-year mortality improvement, i.e., $r(x, t) = \log(\mu(a, t)) - \log(\mu(a, t + 1))$, which

303 is analogous to $\rho(x, t)$ as described above. We calculated the values such as $h(t)$, $\bar{H}(t)$,
304 and a^H in a discretized manner regarding ages, which has been previously described
305 elsewhere.^{22,35}

306 **Software**

307 All analyses used R version 4.2.2.³⁷

308

309 **References**

- 310 1. Bilal, U. *et al.* Life expectancy and mortality in 363 cities of Latin America.
311 *Nature Medicine* 2021 27:3 **27**, 463–470 (2021).
- 312 2. Wang, H. *et al.* Estimating excess mortality due to the COVID-19 pandemic: a
313 systematic analysis of COVID-19-related mortality, 2020-21. *Lancet* **399**, 1513–
314 1536 (2022).
- 315 3. Msemburi, W. *et al.* The WHO estimates of excess mortality associated with the
316 COVID-19 pandemic. *Nature* 2022 613:7942 **613**, 130–137 (2022).
- 317 4. Schumacher, A. E. *et al.* Global age-sex-specific mortality, life expectancy, and
318 population estimates in 204 countries and territories and 811 subnational
319 locations, 1950–2021, and the impact of the COVID-19 pandemic: a
320 comprehensive demographic analysis for the Global Burden of Disease Study
321 2021. *The Lancet* **0**, (2024).
- 322 5. Schöley, J. *et al.* Life expectancy changes since COVID-19. *Nature Human*
323 *Behaviour* 2022 6:12 **6**, 1649–1659 (2022).
- 324 6. Aburto, J. M. *et al.* Quantifying impacts of the COVID-19 pandemic through
325 life-expectancy losses: a population-level study of 29 countries. *Int J Epidemiol*
326 **51**, 63–74 (2022).
- 327 7. Watson, O. J. *et al.* Global impact of the first year of COVID-19 vaccination: a
328 mathematical modelling study. *Lancet Infect Dis* **22**, 1293–1302 (2022).
- 329 8. Link-Gelles, R. *et al.* Estimation of COVID-19 mRNA Vaccine Effectiveness
330 and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4
331 and BA.5 Sublineage Periods. *JAMA Netw Open* **6**, e232598–e232598 (2023).

- 332 9. Rossman, H. *et al.* Hospital load and increased COVID-19 related mortality in
333 Israel. *Nature Communications* 2021 12:1 **12**, 1–7 (2021).
- 334 10. Hayashi, K. & Nishiura, H. Time-dependent risk of COVID-19 death with
335 overwhelmed health-care capacity in Japan, 2020–2022. *BMC Infect Dis* **22**, 1–
336 10 (2022).
- 337 11. French, G. *et al.* Impact of Hospital Strain on Excess Deaths During the COVID-
338 19 Pandemic — United States, July 2020–July 2021. *MMWR Morb Mortal Wkly*
339 *Rep* **70**, 1613–1616 (2021).
- 340 12. Knight, R. *et al.* Association of COVID-19 With Major Arterial and Venous
341 Thrombotic Diseases: A Population-Wide Cohort Study of 48 Million Adults in
342 England and Wales. *Circulation* **146**, 892–906 (2022).
- 343 13. Raisi-Estabragh, Z. *et al.* Cardiovascular disease and mortality sequelae of
344 COVID-19 in the UK Biobank. *Heart* **109**, 119–126 (2023).
- 345 14. Lee, W. E. *et al.* Direct and indirect mortality impacts of the COVID-19
346 pandemic in the United States, March 1, 2020 to January 1, 2022. *Elife* **12**,
347 (2023).
- 348 15. Kayano, T. *et al.* Number of averted COVID-19 cases and deaths attributable to
349 reduced risk in vaccinated individuals in Japan. *Lancet Reg Health West Pac* **28**,
350 (2022).
- 351 16. Andrews, N. *et al.* Covid-19 Vaccine Effectiveness against the Omicron
352 (B.1.1.529) Variant. *New England Journal of Medicine* **386**, 1532–1546 (2022).
- 353 17. Carabelli, A. M. *et al.* SARS-CoV-2 variant biology: immune escape,
354 transmission and fitness. *Nature Reviews Microbiology* 2023 21:3 **21**, 162–177
355 (2023).
- 356 18. Munira, M. S., Okada, Y. & Nishiura, H. Life-expectancy changes during the
357 COVID-19 pandemic from 2019–2021: estimates from Japan, a country with low
358 pandemic impact. *PeerJ* **11**, e15784 (2023).
- 359 19. Woolf, S. H., Masters, R. K. & Aron, L. Y. Effect of the covid-19 pandemic in
360 2020 on life expectancy across populations in the USA and other high income
361 countries: simulations of provisional mortality data. *BMJ* **373**, 1343 (2021).
- 362 20. Nomura, S. *et al.* Excess deaths from COVID-19 in Japan and 47 prefectures
363 from January through June 2021. *Public Health* **203**, 15–18 (2022).
- 364 21. Excess and Exiguous Deaths Dashboard in Japan. Total Number of Deaths |
365 exdeaths-japan.org. <https://exdeaths-japan.org/en/graph/numberof> (2023).

- 366 22. Aburto, J. M., Villavicencio, F., Basellini, U., Kjærgaard, S. & Vaupel, J. W.
367 Dynamics of life expectancy and life span equality. *Proc Natl Acad Sci U S A*
368 **117**, 5250–5259 (2020).
- 369 23. Colchero, F. *et al.* The emergence of longevous populations. *Proc Natl Acad Sci*
370 *U S A* **113**, E7681–E7690 (2016).
- 371 24. Cabinet Secretariat of the Japanese Government. COVID-19 Vaccine
372 informations.(in Japanese).
373 <https://www.kantei.go.jp/jp/headline/kansensho/vaccine.html> (2024).
- 374 25. Burn, E. *et al.* Venous or arterial thrombosis and deaths among COVID-19 cases:
375 a European network cohort study. *Lancet Infect Dis* **22**, 1142–1152 (2022).
- 376 26. Naghavi, M. *et al.* Global burden of 288 causes of death and life expectancy
377 decomposition in 204 countries and territories and 811 subnational locations,
378 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021.
379 *The Lancet* **0**, (2024).
- 380 27. Okada Y & Nishiura H. Supplementary references for open data used in
381 ‘Changes in life expectancy and life span equality during the COVID-19
382 epidemic in Japan up to 2022.’ Preprint at (2024).
- 383 28. United Nations Statistics Division. Birth and Death Registration Completeness
384 Last update: April 2023. [https://unstats.un.org/unsd/demographic-](https://unstats.un.org/unsd/demographic-social/crvs/documents/2023-completeness.xlsx)
385 [social/crvs/documents/2023-completeness.xlsx](https://unstats.un.org/unsd/demographic-social/crvs/documents/2023-completeness.xlsx) (2023).
- 386 29. National Institute of Population and Social Security Research. The Japanese
387 Mortality Database | National Institute of Population and Social Security
388 Research. <https://www.ipss.go.jp/p-toukei/JMD/index-en.asp> (2023).
- 389 30. Ministry of Health Labour and Welfare. Vital Statistics Vital statistics of Japan
390 Final data General mortality | File | Browse Statistics | Portal Site of Official
391 Statistics of Japan. [https://www.e-stat.go.jp/en/stat-](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00450011&tstat=000001028897&cycle=7&tclass1=000001053058&tclass2=000001053061&tclass3=000001053065&cycle_facet=tclass1&tclass4val=0)
392 [search/files?page=1&layout=datalist&toukei=00450011&tstat=000001028897&c](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00450011&tstat=000001028897&cycle=7&tclass1=000001053058&tclass2=000001053061&tclass3=000001053065&cycle_facet=tclass1&tclass4val=0)
393 [ycle=7&tclass1=000001053058&tclass2=000001053061&tclass3=00000105306](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00450011&tstat=000001028897&cycle=7&tclass1=000001053058&tclass2=000001053061&tclass3=000001053065&cycle_facet=tclass1&tclass4val=0)
394 [5&cycle_facet=tclass1&tclass4val=0](https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00450011&tstat=000001028897&cycle=7&tclass1=000001053058&tclass2=000001053061&tclass3=000001053065&cycle_facet=tclass1&tclass4val=0) (2024).
- 395 31. Ministry of Health Labour and Welfare. Visualizing the data: information on
396 COVID-19 infections. <https://covid19.mhlw.go.jp/en/> (2023).
- 397 32. Arriaga, E. E. Measuring and explaining the change in life expectancies.
398 *Demography* **21**, 83–96 (1984).
- 399 33. Arriaga, E. E. Changing Trends in Mortality Decline during the Last Decades. in
400 *Differential Mortality* 105–129 (1989).
401 doi:10.1093/oso/9780198288824.003.0006.

- 402 34. Keyfitz, N. Mortality Comparisons; The Male-Female Ratio. 54–76 (1985)
403 doi:10.1007/978-1-4757-1879-9_3.
- 404 35. Aburto, J. M., Alvarez, J. A., Villavicencio, F. & Vaupel, J. W. The threshold age
405 of the lifetable entropy. *Demogr Res* **41**, 83–102 (2019).
- 406 36. Demetrius, L. Demographic Parameters and Natural Selection. *Proceedings of*
407 *the National Academy of Sciences* **71**, 4645–4647 (1974).
- 408 37. R Core Team. R: The R Project for Statistical Computing. [https://www.r-](https://www.r-project.org/)
409 [project.org/](https://www.r-project.org/) (2023).

410

411

412 **Acknowledgment**

413 Y.O. received funding from the SECOM Science and Technology Foundation. H.N.

414 received funding from Health and Labour Sciences Research Grants (grant numbers

415 20CA2024, 21HB1002, 21HA2016, and 23HA2005), the Japan Agency for Medical

416 Research and Development (grant numbers JP23fk0108612 and JP23fk0108685), JSPS

417 KAKENHI (grant numbers 21H03198 and 22K19670), the Environment Research and

418 Technology Development Fund (grant number JPMEERF20S11804) of the

419 Environmental Restoration and Conservation Agency of Japan, Kao Health Science

420 Research, the Daikin GAP Fund of Kyoto University, the Japan Science and

421 Technology Agency SICORP program (grant numbers JPMJSC20U3 and

422 JPMJSC2105), and the RISTEX program for Science, Technology, and Innovation

423 Policy (grant number JPMJRS22B4). We thank Melissa Leffler, MBA, of Edanz

424 (<https://jp.edanz.com/ac>) for editing a draft of this manuscript.

425

426 **Author contributions**

427 All authors participated in the study design. Y.O. collected and retrieved the data,
428 conducted the main analysis, and H.N. validated the analysis. Y.O. wrote the first draft
429 of the paper and created figures and tables. H.N. edited the earlier versions of the
430 manuscript. All authors read and approved the final version of the manuscript.

431 **Data availability**

432 We used openly accessible COVID-19 statistics from the website of the Ministry of
433 Health, Labour and Welfare, and life tables and related statistics from the website of
434 National Institute of Population and Social Security Research. The supplementary files
435 include the datasets used in this study, and also the results of our numerical analyses.
436 None of the data used in this study contained personally identifiable information.

437

438 **Additional information**

439 **Supplementary Information:** The online version contains supplementary material
440 available at [doi:xxx](#)

441 **Correspondence:** to Hiroshi Nishiura.

442 **Competing interest:** The authors declare no competing interest.

443 **Ethical declarations:** Ethical approval was not required because none of the data used

444 in this study included any personally identifiable information.

445

446 **Figure 1. Life expectancy changes from 2019–20, 2020–21, and 2021–22 by**
447 **prefecture.**

448 Changes from (A) 2019–20, (B) 2020–21, and (C) 2021–22 are shown. In each panel,
449 bars in blue show positive changes, and red bars show negative changes. Prefectures are
450 shown in ascending order by life expectancy change in 2021–22.

451

452 **Figure 2. Correlation between life expectancy changes and COVID-19 burden**
453 **from official statistics.**

454 Correlation between life expectancy changes and the reported numbers of (A) annual
455 COVID-19 cases, (B) person-days in intensive care due to COVID-19, and (C) deaths
456 due to COVID-19 are shown. The variables on the x-axis are log-scaled in all panels. In
457 each panel, individual prefectures are shown as black triangles for 2020–21 data, or red
458 dots for 2021–22 data. The horizontal dashed line corresponds to “no year-on-year life
459 expectancy change”.

460

461 **Figure 3. Arriaga decomposition of life expectancy change by major cause of death**
462 **and age group, for the total population of Japan.**

463 Decomposed contribution by age for (A) 2019–20, (B) 2020–21, (C) 2021–22 are
464 shown in each panel. The key to the colors of bars for each major cause are shown in
465 the panel below the plots. Bars representing major causes with a positive contribution to
466 life expectancy are stacked on the right-hand side, and those making negative
467 contributions are stacked on the left-hand side.

468

469 **Figure 4. The trend in life span equality from 2000 to 2022, for the total population**
470 **of Japan.**

471 Panel (A) shows the dynamics of life span equality by time from 2000 to 2022. Panel
472 (B) shows the same dynamics in relation to life expectancy for the same period, and the
473 years corresponding to the red dots are noted within the figure.

474

475 **Figure 5. Weight of change in life span equality and mortality improvement by**
476 **age, total population.**

477 Panel (A) shows the weight $w(x, t)W_h(x, t)$ for $t = 2022$ (solid blue line) and $t =$
478 2021 (dashed red line). Panel (B) describes the year-on-year mortality improvement
479 $r(x, t) = \log(\mu(a, t)) - \log(\mu(a, t + 1))$ for $t = 2020$ (red), $t = 2021$ (green), and
480 $t = 2022$ (blue). Vertical dashed lines in both panels represent the threshold age $a^H =$
481 84.10 for 2022.

482 **Table 1. Life expectancy change and COVID-19 statistics: summary of linear**
483 **regression analysis.**

484

COVID-19 data (log-scale)	Year	Coefficient (95% CI*)	Intercept (95% CI)
Cases	2020-21	-0.104 (-0.189, -0.018)	-0.655 (-1.086, -0.224)
	2021-22	-0.104 (-0.496, 0.288)	-0.652 (-1.266, -0.037)
Person-days in intensive care	2020-21	-0.082 (-0.144, -0.021)	-0.704 (-1.132, -0.277)
	2021-22	-0.053 (-0.117, 0.011)	-0.879 (-1.353, -0.405)
Death	2020-21	-0.067 (-0.137, -0.002)	-0.789 (-1.464, -0.114)
	2021-22	-0.105 (-0.269, 0.060)	-1.338 (-2.671, -0.057)


485 *CI, confidence interval

486


487

Life expectancy changes (years) by prefecture, Total Population


(A) 2019-20




(B) 2020-21




(C) 2021-22




Life expectancy changes (years) and reported COVID-19 burden by prefecture




(A) 2019-20



(B) 2020-21




(C) 2021-22




Cause of Death

Neoplastic	Respiratory	Nervous	Genitourinary or Renal	Mental
Cardiovascular	External	Digestive	COVID-19	Others


(A) Trend of h , 2000-22



(B) Life Expectancy at Birth and h , 2000-22



(A) $w(x)Wh(x)$, Total Population



(B) Year-on-year Mortality improvement, Total Population

